Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jenny Prince"'
Autor:
Udai Banerji, James Spicer, Chris Twelves, Keith Jones, Jenny Prince, Michiyasu Inatani, Rie Shiokawa, Kohei Noguchi, Lorna Pope, Ruth Riisnaes, Karen Swales, Shaun Decordova, Alan Anthoney, David J. Pinato, Andrea Zivi, Chara Stavraka, Debra Josephs, Aurelius Olmin, Sarah Blagden
Purpose: This phase I dose-escalation study investigated the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of CH5132799.Experimental Design: Patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ed189fa64b7b088337fb60175edcfbd
https://doi.org/10.1158/1078-0432.c.6523124
https://doi.org/10.1158/1078-0432.c.6523124
Autor:
Udai Banerji, James Spicer, Chris Twelves, Keith Jones, Jenny Prince, Michiyasu Inatani, Rie Shiokawa, Kohei Noguchi, Lorna Pope, Ruth Riisnaes, Karen Swales, Shaun Decordova, Alan Anthoney, David J. Pinato, Andrea Zivi, Chara Stavraka, Debra Josephs, Aurelius Olmin, Sarah Blagden
Supplementary Data. Inclusion and exclusion criteria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28a56fcb2c772352916f470719b5e1bf
https://doi.org/10.1158/1078-0432.22455818.v1
https://doi.org/10.1158/1078-0432.22455818.v1
Publikováno v:
The International Journal of Humanities & Social Studies. 7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88da377a8ad5304bab586d677706caf5
https://doi.org/10.24940/2019/v7/i3/hs1903-054
https://doi.org/10.24940/2019/v7/i3/hs1903-054
Autor:
Kohei Noguchi, Aneta Suder, Simon P. Heaton, Debashis Sarker, Philippe A. Cassier, Roshan Agarwal, Sarah P. Blagden, Shaun Decordova, David J. Pinato, Chara Stavraka, Udai Banerji, Jenny Prince, Michiyasu Inatani, Lorna Pope, Rie Shiokawa, Aurelius Omlin, Suzanne Wendy Allan, Keith Jones, Monsterrat Blanco, James Spicer
Publikováno v:
Journal of Clinical Oncology. 30:3022-3022
3022 Background: The phosphatidylinositol 3-kinase (PI3K) pathway is a promising target in cancer. CH5132799 is a novel PI3K inhibitor, selectively inhibiting class I PI3Ks (α, β, δ and γ) with no inhibition of class II and III or mTOR, and with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7afbe0edf6803c8c1f66b3474c6fc357
https://doi.org/10.1200/jco.2012.30.15_suppl.3022
https://doi.org/10.1200/jco.2012.30.15_suppl.3022